European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week

MT NewswiresMar 7 11:14 ET

Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289

Moomoo NewsMar 6 07:33 ET · Ratings

TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $162

Moomoo NewsMar 5 08:31 ET · Ratings

Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200

Moomoo NewsFeb 25 14:31 ET · Ratings

Express News | Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

BenzingaFeb 25 09:17 ET

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswireFeb 24 16:01 ET

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180

Moomoo NewsFeb 24 08:31 ET · Ratings

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

PR NewswireFeb 20 11:01 ET

Why Is BioMarin Stock Trading Higher On Thursday?

BenzingaFeb 20 09:39 ET

Express News | Form 144 | Ascendis Pharma A/S(ASND.US) Officer Proposes to Sell 6.01 Million in Common Stocks

Moomoo NewsFeb 19 17:13 ET

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

BenzingaFeb 19 10:03 ET

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $180 to $289

Moomoo NewsFeb 19 08:00 ET · Ratings

Express News | Ascendis Pharma Shares Are Trading Higher After Evercore ISI Raised Its Price Target on the Stock From $220 to $260

BenzingaFeb 18 15:29 ET

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading

MT NewswiresFeb 18 11:03 ET

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow JonesFeb 18 10:38 ET · Ratings

The 19% Return This Week Takes Ascendis Pharma's (NASDAQ:ASND) Shareholders Three-year Gains to 29%

Simply Wall StFeb 15 07:51 ET

The Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results Are Out And Analysts Have Published New Forecasts

Simply Wall StFeb 15 07:43 ET

Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $220

Moomoo NewsFeb 14 08:34 ET · Ratings

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $168 to $225

Moomoo NewsFeb 14 08:00 ET · Ratings

Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

Yahoo FinanceFeb 14 00:00 ET